In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.
HIV/AIDS prevention can be difficult in countries with limited resources, especially when it comes to the millions of affected children who are less likely to tolerate antiretroviral drugs. In an effort to overcome this challenge, researchers at Penn State University have developed a delivery system for the antiretroviral Ritonavir that uses a protein in cow's milk for oral administration of the drug.
Some Indian companies that had put off production of HIV/AIDS meds while they waited for the government to sign contracts are now having to seriously ramp up because of shortages of some meds, Reuters reports.
New technology has allowed researchers to view HIV proteins in action, zooming in on so-called spikes that help the virus bind to cells it infects. The research puts scientists one step closer to a vaccine that could effectively prevent transmission of HIV and halt the spread of AIDS, an international epidemic.
A new sheds light on three different factors that may have contributed to ridding HIV from the "Berlin patient."
Unfortunately, the biggest news coming out of the 20th International AIDS Conference involves the researchers who were killed on their way there.
California diagnostic maker Zyomyx pulled in $7.5 million from World Health Organization-hosted UNITAID to support commercialization of its MyT4 point-of-care CD4 test for HIV/AIDS in the developing world.
While antiretroviral therapies and preventive measures have helped lessen the impact of HIV, leaders at the National Institutes of Health think a safe, moderately effective vaccine is still needed.
In the 25 years since the first World AIDS Day, patient outcomes have improved significantly, but the long-sought-after vaccine remains elusive. As the world commemorated the event this week, two very different projects outlined their plans to combat the virus.
Scientists have unraveled one of the mysteries of HIV--they've mapped out the structure of an envelope protein within the virus, long known as an extremely difficult target.